Overview

A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

Status:
Completed
Trial end date:
2008-02-19
Target enrollment:
Participant gender:
Summary
This study was conducted to test the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Amicus Therapeutics